UH Cleveland study finds no extra dementia risk from anticholinergics in 830,393 patients

Researchers from the Urology Institute at University Hospitals Cleveland Medical Center analyzed health records from 830,393 adult patients aged 40 to 90 who initiated therapy for overactive bladder between 2012 and 2025. According to a report by news-medical.net on a study published in JAMA Network Open, the incidence of dementia was comparable between patients prescribed anticholinergic medications and those receiving newer beta-3 agonists news-medical.netnews-medical.netnews-medical.netOpen source ↗.

Comparison of Drug Classes

The authors extracted data using the Epic Cosmos national electronic health record database to examine long-term cognitive outcomes. Anticholinergic drugs serve as a foundational, second-line pharmacological therapy for overactive bladder, whereas beta-3 adrenergic receptor agonists represent a newer class previously presumed to carry less risk for brain health. The analysis demonstrated that dementia rates did not significantly differ between these two medication classes or across individual pharmaceutical agents. Lead author David Sheyn stated that earlier observational studies linking anticholinergics to dementia typically monitored cohorts for five years or fewer, while underlying neurodegenerative processes often begin decades prior to clinical manifestation.

Study Constraints and Clinical Context

The observed correlation aligns with the hypothesis that overactive bladder itself, alongside related neuroregulatory disruptions leading to urinary incontinence, may represent an early manifestation of neurodegenerative changes associated with frontal cortical dysfunction. However, the investigation only evaluated patients receiving active pharmacotherapy and did not include an untreated control cohort; consequently, it cannot verify the complete absence of medication-induced risk or definitively confirm that the bladder condition is an autonomous prodrome. The authors also noted that while anticholinergics can produce transient cognitive and memory side effects in some individuals, these symptoms resolve upon drug discontinuation. The team stated that the findings require independent replication before clinical guidelines are altered, and beta-3 agonists remain the preferred option when feasible.